CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A

CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A, Volume 208 represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. CRISPR-Cas9 system is being used in microbial genome editing, mammalian genome editing, disease models, and more. It has shown potential in human disease treatment. However, it is not easy to find CRISPR-Cas systems genome editing in a single source.

This volume offers CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease, fungal disease, stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders. In addition, it highlights a number of aspects of the CRISPR-Cas systems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.

• Updares on CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease and fungal disease
• Discusses stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders
• Includes commentary on CRISPR in autoimmune and blood disorders

Elsevier Science & Technology